MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · Real-Time Price · USD
6.55
+0.63 (10.64%)
At close: Jul 21, 2025, 4:00 PM
6.68
+0.13 (1.98%)
Pre-market: Jul 22, 2025, 8:30 AM EDT
Company Description
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors.
The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
MEI Pharma, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Dec 19, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Justin File |
Contact Details
Address: 9920 Pacific Heights Blvd., Suite 150 San Diego, California 92121 United States | |
| Phone | 858 369 7100 |
| Website | meipharma.com |
Stock Details
| Ticker Symbol | MEIP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001262104 |
| CUSIP Number | 55279B202 |
| ISIN Number | US55279B3015 |
| Employer ID | 51-0407811 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin J. File CPA | Acting Chief Executive Officer, Chief Financial Officer and Corporate Secretary |
| Nicole Chyoko Iida | Vice President of Legal Affairs |
| Anne Frese | Chief People Officer |
| Dr. Robert D. Mass M.D. | Strategic Advisor |
| David A. Walsey J.D., L.L.M. | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Mar 7, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 10-Q | Quarterly Report |
| Jan 31, 2025 | 8-K | Current Report |
| Dec 20, 2024 | ARS | Filing |
| Dec 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 20, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 25, 2024 | 8-K | Current Report |